We are a pioneer in the CDMO industry, setting the pace with cutting-edge science and smart technology to make the medicines of tomorrow.
Joined July 2009
- Tweets 2,604
- Following 255
- Followers 8,003
- Likes 972
1,290 Photos and videos
May 12
We have announced the launch of Xcite® AAV Stable Producer Cell Line technology to help gene therapy developers address scalability, cost of goods and process robustness as programs progress towards commercialization. Read more here: ow.ly/E9TI50YY9KO
#Lonza #CDMO #AAV
142
May 8
In our Q1 qualitative update, Lonza reported a strong performance in line with expectations for Full-Year Outlook 2026, despite a changing geopolitical and macroeconomic environment. Read more here: ow.ly/10zM50YWnSt
#Lonza #Growth #CDMO #Pharmaceutical #Biotechnology
1
163
Apr 1
Today, we published our 2025 Annual and Sustainability Reports, providing a comprehensive overview of our performance and progress in executing the One Lonza strategy.
Explore the reports here: lonza.com/investor-relations…
#Lonza #CDMO #Growth #Sustainability #AnnualReport
206
Mar 26
We have announced the launch of our Media Development Lab at our Singapore site, designed to optimize cell culture media development and facilitate a smooth transition to manufacturing. Read more here: ow.ly/flGo50Yzbsr
#Lonza #CDMO #Bioprocessing #CellCulture
1
260
Mar 9
We have extended our long-term commercial manufacturing agreement with Genetix Biotherapeutics. The agreement will focus on expanding manufacturing capacity at Lonza's Houston cell and gene therapy facility. Read more: ow.ly/P9v450YrcYo
#Lonza #CDMO #CellTherapy
1
203
Mar 6
Today, we signed an agreement to divest our Capsules & Health Ingredients business to Lone Star for an enterprise value of CHF 2.3 bn (USD 3 bn) at closing. The transaction completes our transformation into a pure-play CDMO. Read more: lonza.com/news/2026-03-06-18…
1
220
Feb 19
We have announced the strengthening of our Advanced Synthesis offering to support ADC discovery, development, and manufacturing.
Read more: ow.ly/KKJj50YhYK0
#Lonza #ADCs #Bioconjugates
194
Jan 28
Today, we reported our financial results for Full-Year 2025, with sales of CHF 6.5 billion and a CORE EDITDA of CHF 2.1 billion resulting in a strong margin of 31.6%, ahead of our upgraded CDMO guidance.
Read more about our progress in FYR 2025 here: ow.ly/M3sb50Y4G54
1
1
7
525
Lonza retweeted
8 Dec 2025
Ambassador Callista L. Gingrich was pleased to meet @LonzaGroup CEO Dr. Wolfgang Wienand and Prof. Dr. Andreas Bohrer to learn about Lonza’s activities in the United States and Switzerland, including Lonza’s support for apprenticeship programs and plans for further expansion in the U.S. market. 🇺🇸🇨🇭 @SelectUSA
3
11
1,237
27 Oct 2025
We have announced the acquisition of Redberry SAS, an innovative company specializing in rapid microbiology testing solutions using solid-phase cytometry technology. The transaction is expected to close in Q4 2025, subject to closing conditions.
lonza.com/media-advisories/2…
2
421
23 Oct 2025
In our Q3 qualitative update, we reported a strong performance and confirmed our upgraded Full-Year 2025 Outlook for both our CDMO business, and our Capsules & Health Ingredients (CHI) business.
ow.ly/UybO50XgGEz
3
371
7 Oct 2025
We have been awarded a Gold medal in the EcoVadis Sustainability rating, with a score putting us in the top 5% of companies assessed.
#Lonza #CDMO #Sustainability #EcoVadisSuccessStory #ESG
374
23 Sep 2025
Today, we announced a collaboration with RION to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond.
Read more: lonza.com/media-advisories/2…
348
23 Jul 2025
We have seen a strong financial performance in H1 2025, with CHF 3.6 billion sales resulting in 19.0% CER sales growth, and a CORE EBITDA of CHF 1.1 billion resulting in a robust margin of 29.6%.
Read more about our progress in H1 2025 here: bit.ly/4lSTbxO
2
1
6
584
Lonza retweeted
15 Jul 2025
📢 We are delighted to announce that @LonzaGroup's Chief #Legal & Corporate Affairs Officer Andreas Bohrer has joined as a Member of our Executive Board to help advocate our mission at the @OECD.
Nominated by our member @economiesuisse, Andreas brings a wealth of experience in legal affairs from his time at #Lonza.
🔎 Our Executive Board ➡️ businessatoecd.org/executive…
5
11
924
22 May 2025
We have just launched our Design2Optimize™ platform, to enhance the process development and manufacturing of small molecule APIs.
bit.ly/43xuorp
2
814
9 May 2025
In our Q1 qualitative update, Lonza reported a strong performance in line with expectations for Full-Year 2025, driven by robust commercial demand in our CDMO business and high utilization in the early-stage business.
bit.ly/433nOZh
4
467
3 Apr 2025
Today we published our Annual Report 2024 and Sustainability Report 2024, giving a comprehensive overview of our progress towards our long-term business and sustainability goals.
bit.ly/4iXTqGA
1
565
1 Apr 2025
Today we launch our simplified and streamlined operating model. Based on our “One Lonza” vision and strategy, this transformation unites our core competencies to fulfil our vision to be a pioneer and world leader in the CDMO industry.
bit.ly/3YdvlDf
1
456
29 Jan 2025
Today, we reported our financial results for Full-Year 2024, with sales of CHF 6.6 billion. A CORE EDITDA of CHF 1.9 billion resulted in a robust margin of 29.0%, driven by high demand for commercial CDMO services and strong operational execution.
lonza.com/news/2025-01-29-06…
5
1,110